Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Johnson & Johnson To Submit More Than 10 New Drug Applications By 2017-WSJ


Thursday, 23 May 2013 01:38pm EDT 

The Wall Street Journal reported that Johnson & Johnson's pharmaceutical unit plans to submit more than 10 new product applications by 2017. Now, J&J expects to seek approval in coming years for new treatments for rheumatoid arthritis, influenza and cancer, executives said Thursday in a meeting with analysts and investors near company headquarters in New Brunswick, N.J. Among the late-stage products for which it plans to file for regulatory approval are simeprevir for hepatitis C, ibrutinib and daratumumab for the treatment of hematologic malignancies, and sirukumab and guselkumab for immune-mediated diseases such as rheumatoid arthritis. 

Company Quote

105.8
-0.24 -0.23%
4:03pm EDT